公开(公告)号：EP4422640A1

公开(公告)日：2024-09-04

申请号：EP22888478.9

申请日：2022-10-26

Applicant: Evofem, Inc.

Inventor： GARG, Sanjay ,  FRANKLIN, Afinjuomo, Olumide ,  SONG, Yunmei

IPC: A61K31/7016 ,  A61K31/715 ,  A61K9/00 ,  A61K31/70

CPC classification number: A61K9/0034 ,  A61K9/7007 ,  A61P15/02 ,  A61K31/717 ,  A61K31/765 ,  A61K31/723 ,  A61K31/19

公开(公告)号：EP4419146A1

公开(公告)日：2024-08-28

申请号：EP22792930.4

申请日：2022-10-19

Applicant: Tijani Holding B.V.

Inventor： TIJANI, Amina

IPC: A61K47/02 ,  A61K47/06 ,  B22F1/102

CPC classification number: A61K47/02 ,  A61K9/0019 ,  A61K9/006 ,  A61K9/5161 ,  A61K9/5192 ,  A61K9/7007 ,  A61K9/06 ,  A61K9/145 ,  A61K47/26 ,  A61K2039/608120130101 ,  A61K39/12 ,  A61P31/20 ,  C12N2750/1003420130101 ,  A61K2039/55220130101 ,  A61P31/14 ,  C12N2770/2003420130101 ,  C12N15/85

公开(公告)号：EP3727352B1

公开(公告)日：2024-08-21

申请号：EP18829502.6

申请日：2018-12-12

IPC: A61K9/70 ,  A61K9/00 ,  A61K47/10 ,  A61K47/36 ,  A61K31/46

CPC classification number: A61K47/10 ,  A61K9/006 ,  A61K47/36 ,  A61K9/7007 ,  A61K31/46

公开(公告)号：EP4408347A2

公开(公告)日：2024-08-07

申请号：EP22877178.8

申请日：2022-09-23

Applicant: Lyra Therapeutics, Inc.

Inventor： CONCAGH, Danny ,  YOU, Changcheng ,  PALASIS, Maria ,  GARTUNG, Allison

IPC: A61F2/18 ,  A61B17/24 ,  A61F2/04 ,  A61K9/70 ,  A61L31/16 ,  A61M31/00 ,  A61F2/90

CPC classification number: A61F2250/006720130101 ,  A61F2210/007620130101 ,  A61F2/88 ,  A61F2/06 ,  A61F2/02 ,  A61F2002/04720130101 ,  A61F2002/04320130101 ,  A61F2/18 ,  A61K9/0004 ,  A61K9/7007 ,  A61L31/16

公开(公告)号：EP3236935B1

公开(公告)日：2024-08-07

申请号：EP15816369.1

申请日：2015-12-22

IPC: A61K9/00 ,  A61K9/70 ,  A61K9/48 ,  A61K31/196 ,  A61K31/56 ,  A61K31/58 ,  A61K45/06 ,  A61M31/00

CPC classification number: A61K9/0031 ,  A61K9/0034 ,  A61K9/0036 ,  A61K9/006 ,  A61K47/32 ,  A61K9/7007 ,  A61K9/703 ,  A61K9/7069 ,  A61K9/7084 ,  A61K45/06 ,  A61K31/196 ,  A61M31/002 ,  A61K9/4808 ,  A61K31/56 ,  A61K31/58

公开(公告)号：EP4351539A1

公开(公告)日：2024-04-17

申请号：EP22820871.6

申请日：2022-06-07

Applicant: University of Mississippi ,  Munivar, Azim ,  Puleo, David Allen

Inventor： WERFEL, Thomas ,  MUNIVAR, Azim ,  PULEO, David Allen

IPC: A61K9/70 ,  A61K9/28 ,  A61K31/137 ,  A61K31/48 ,  A61L27/54 ,  A61P25/24

CPC classification number: A61K31/137 ,  A61P25/24 ,  A61K31/48 ,  A61K31/4045 ,  A61K31/4745 ,  A61K31/675 ,  A61K9/0024 ,  A61K9/209 ,  A61K9/7007 ,  A61K47/38 ,  A61K47/10

公开(公告)号：EP2768540B1

公开(公告)日：2018-12-05

申请号：EP12841666.6

申请日：2012-10-17

Applicant: St. Teresa Medical, Inc.

Inventor： OLSON, Curtis E. ,  MESSINA, Philip A.

IPC: A61L15/44 ,  A61K38/36 ,  A61F13/00 ,  A61K38/48 ,  A61K47/36

CPC classification number: A61L15/44 ,  A61K9/7007 ,  A61K38/363 ,  A61K38/4833 ,  A61K47/36 ,  A61K49/00 ,  A61L15/28 ,  A61L2300/418 ,  A61L2400/04 ,  A61M5/00 ,  A61M25/02 ,  A61M25/10 ,  C12Y304/21005 ,  C08L5/02

Abstract: A method of forming hemostatic sheets. Dextran and water are mixed to form a dextran-water mixture. The dextran-water mixture is formed into a first support layer. Fibrinogen and thrombin are mixed to form a fibrinogen and thrombin mixture. The fibrinogen and thrombin mixture is dispersed on the first support layer to form a hemostatic sheet.

公开(公告)号：EP3400964A1

公开(公告)日：2018-11-14

申请号：EP17736173.0

申请日：2017-01-09

Applicant: CTC Bio, Inc.

Inventor： JEON, Hong Ryeol ,  LEE, Bong-Sang ,  PARK, Su-Jun ,  HAN, Jiyeong ,  KIL, Myeongcheol ,  KIM, Min Seop ,  MEANG, Seul Ki

IPC: A61K47/30 ,  A61K9/00 ,  A61K31/498 ,  A61K31/4985

CPC classification number: A61K31/55 ,  A61K9/10 ,  A61K9/1629 ,  A61K9/2022 ,  A61K9/7007 ,  A61K47/30

Abstract: The present disclosure relates to a pharmaceutical preparation having varenicline or a pharmaceutically acceptable salt thereof as an active ingredient. More particularly, it relates to an orally administered pharmaceutical preparation which allows limited use of a sweetening agent or a flavoring agent by effectively masking the unique taste of varenicline, particularly bitterness, which is a bitter and burning taste, and ensures convenience in taking the pharmaceutical preparation by being orally administrable without irritation, while containing a pharmaceutically effective amount of varenicline or a pharmaceutically acceptable salt thereof, and a method for preparing the same.

公开(公告)号：EP2540318B1

公开(公告)日：2018-10-24

申请号：EP11744790.4

申请日：2011-02-21

Applicant: Daiichi Sankyo Company, Limited

Inventor： KANAMARU, Taro ,  TAJIRI, Shinichiro ,  FUKUI, Sachiko ,  YOSHIDA, Kazuhiro

IPC: A61K9/22 ,  A61K31/403 ,  A61K31/4745 ,  A61P7/02

CPC classification number: A61K9/2054 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2077 ,  A61K9/5047 ,  A61K9/7007 ,  A61K31/403 ,  A61K31/437 ,  A61K31/4745 ,  A61K31/522

Abstract: It is intended to avoid dose dumping of a drug and improve the dissolution properties of the drug in the lower gastrointestinal tract, and thereby provide a sustained-release matrix preparation for oral administration that reliably exhibits its main pharmacological effect when orally administered once or twice a day. The present invention provides a sustained-release preparation obtained by mixing of (A) a pharmacologically active drug, (B) hydroxypropyl methylcellulose acetate succinate having a median size (D 50 ) of 40 µm or smaller, (C) a cellulose derivative, and (D) a saccharide or a nonionic water-soluble polymer followed by molding.

公开(公告)号：EP3193826B1

公开(公告)日：2018-10-17

申请号：EP15732161.3

申请日：2015-06-19

Applicant: Pharmathen S.A.

Inventor： KARAVAS, Evangelos ,  KOUTRIS, Efthymios ,  SAMARA, Vasiliki ,  KOUTRI, Ionna ,  KALASKANI, Anastasia ,  KALANTZI, Lida ,  KAKOURIS, Andreas ,  DIAKIDOU, Amalia ,  GOTZAMANIS, George ,  GEORGOUSIS, Zaharias ,  KONSTANTI, Louiza

IPC: A61K38/05 ,  A61K47/02 ,  A61K47/10 ,  A61K47/26 ,  A61K47/36 ,  A61K9/70 ,  A61K31/401 ,  A61K9/00

CPC classification number: A61K38/05 ,  A61K9/0056 ,  A61K9/7007 ,  A61K31/401 ,  A61K47/02 ,  A61K47/10 ,  A61K47/26 ,  A61K47/36

Abstract: The present invention relates to an oral applicable therapeutic dosage form, in particular an orodispersible film comprising Enalapril or pharmaceutically acceptable salts thereof for use in the treatment of hypertension in a pediatric population. The pediatric population is defined from 1 to 18 years of age. The present invention also provides a method of manufacturing of such a dosage form.